Press releases
Press releases.
March 14th 2023
press releases
February 6th 2023
press releases
January 30th 2023
press releases
Investor updates
Investor updates.
Analyst reports
Analyst reports.
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)
March 14th 2023
analyst reports
CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)
March 7th 2023
analyst reports
Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)
February 28th 2023
analyst reports